PubRank

B G Taal

Author PubWeight™ 57.30‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 1996 3.54
2 MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families. J Clin Oncol 2001 2.71
3 Quality of life in colorectal cancer. Stoma vs. nonstoma patients. Dis Colon Rectum 1995 2.15
4 Decision analysis in the management of duodenal adenomatosis in familial adenomatous polyposis. Gut 1997 1.88
5 Gastric non-Hodgkin lymphomas of mucosa-associated lymphoid tissue are not associated with more aggressive Helicobacter pylori strains as identified by CagA. Am J Clin Pathol 1996 1.84
6 A cost-effectiveness analysis of colorectal screening of hereditary nonpolyposis colorectal carcinoma gene carriers. Cancer 1998 1.49
7 The risk of brain tumours in hereditary non-polyposis colorectal cancer (HNPCC). Int J Cancer 1996 1.35
8 Epidemiology and survival in patients with carcinoid disease in The Netherlands. An epidemiological study with 2391 patients. Ann Oncol 2001 1.33
9 Histological grading in gastric lymphoma: pretreatment criteria and clinical relevance. Gastroenterology 1997 1.30
10 Expression of oestrogen receptor and loss of E-cadherin are diagnostic for gastric metastasis of breast carcinoma. Histopathology 2005 1.27
11 Clinical heterogeneity of familial colorectal cancer and its influence on screening protocols. Gut 1994 1.09
12 Hereditary nonpolyposis colorectal cancer: results of long-term surveillance in 50 families. Eur J Cancer 1995 1.04
13 Evaluation of (111)In-pentetreotide, (131)I-MIBG and bone scintigraphy in the detection and clinical management of bone metastases in carcinoid disease. Nucl Med Commun 2002 1.04
14 Increased risk of lung cancer, non-Hodgkin's lymphoma, and leukemia following Hodgkin's disease. J Clin Oncol 1989 1.01
15 Toxicity grading systems. A comparison between the WHO scoring system and the Common Toxicity Criteria when used for nausea and vomiting. Ann Oncol 1994 1.00
16 Probabilities for a probabilistic network: a case study in oesophageal cancer. Artif Intell Med 2002 0.98
17 Controversies and consensus in the diagnosis, work-up and treatment of gastric lymphoma: an international survey. Ann Oncol 1999 0.98
18 Treatment results of primary stage I and II non-Hodgkin's lymphoma of the stomach. Radiother Oncol 1988 0.96
19 Reactivity to human papillomavirus type 16 L1 virus-like particles in sera from patients with genital cancer and patients with carcinomas at five different extragenital sites. Br J Cancer 2003 0.95
20 Non-allelic heterogeneity of familial adenomatous polyposis. Am J Med Genet 1993 0.92
21 EAP in advanced gastric cancer. J Clin Oncol 1990 0.91
22 A tumour with a neuroendocrine and papillary serous component: two or a pair? J Clin Pathol 2002 0.91
23 Clinical diagnosis of primary biliary cirrhosis: a classification based on major and minor criteria. Hepatogastroenterology 1983 0.89
24 The role of I-131-MIBG in the diagnosis and therapy of carcinoids. Eur J Nucl Med 1987 0.88
25 Strong BCL10 nuclear expression identifies gastric MALT lymphomas that do not respond to H pylori eradication. Gut 2006 0.88
26 Role of natriuretic peptides in the diagnosis and treatment of patients with carcinoid heart disease. Br J Cancer 2004 0.87
27 Computer-based decision support in the management of primary gastric non-Hodgkin lymphoma. Methods Inf Med 1998 0.85
28 Intestinal obstruction due to diffuse peritoneal fibrosis at 2 years after the successful treatment of malignant peritoneal mesothelioma with intraperitoneal mitoxantrone. Cancer Chemother Pharmacol 1992 0.83
29 Thymidylate synthase expression in patients with colorectal carcinoma using a polyclonal thymidylate synthase antibody in comparison to the TS 106 monoclonal antibody. J Histochem Cytochem 2000 0.82
30 Serum IgM in primary biliary cirrhosis. Clin Chim Acta 1980 0.82
31 Renal excretion of meta-iodobenzylguanidine after therapeutic doses in cancer patients and its relation to dose and creatinine clearance. Nucl Med Commun 1995 0.82
32 Pleuropulmonary fibrosis associated with chronic and excessive intake of ergotamine. Thorax 1983 0.81
33 An elevated progastrin-releasing peptide level in patients with well-differentiated neuroendocrine tumours indicates a primary tumour in the lung and predicts a shorter survival. Ann Oncol 2011 0.81
34 Low therapeutic value of D-penicillamine in a short-term prospective trial in primary biliary cirrhosis. Liver 1983 0.81
35 Results of a phase II trial of epirubicin and cisplatin (EP) before and after irradiation and 5-fluorouracil in locally advanced pancreatic cancer: an EORTC GITCCG study. Eur J Cancer 1996 0.80
36 A dose-escalation study of recombinant interferon-alpha in patients with a metastatic carcinoid tumour. Eur J Cancer 1992 0.80
37 Long-term palliation in metastatic carcinoid tumours with various applications of meta-iodobenzylguanidin (MIBG): pharmacological MIBG, 131I-labelled MIBG and the combination. Eur J Gastroenterol Hepatol 1999 0.80
38 Carcinoid heart disease: an update. Scand J Gastroenterol Suppl 2002 0.78
39 Discontinuation of proton pump inhibitors during assessment of chromogranin A levels in patients with neuroendocrine tumours. Br J Cancer 2011 0.78
40 CagA+ H. pylori strains and gastric lymphoma. Gastroenterology 1997 0.78
41 [Periodic colonoscopic examinations of persons with a positive family history for colorectal cancer. Work Group 'Hereditary non-polyposis- colon-rectum cancers']. Ned Tijdschr Geneeskd 1999 0.78
42 Surgical intervention for complications caused by late radiation damage of the small bowel: a retrospective analysis. Eur J Surg Oncol 1993 0.77
43 Risk factors for the development of oesophageal cancer as a second primary tumour. Eur J Cancer 1995 0.77
44 High-performance liquid chromatographic determination of metaiodobenzylguanidine in whole blood and plasma of cancer patients. J Pharm Biomed Anal 1994 0.77
45 Interferon and meta-iodobenzylguanidin combinations in the treatment of metastatic carcinoid tumours. Endocr Relat Cancer 2004 0.77
46 Expression and ligand binding of bombesin receptors in pulmonary and intestinal carcinoids. J Endocrinol Invest 2010 0.77
47 Enhancement of 131I-MIBG uptake in carcinoid tumours by administration of unlabelled MIBG. Nucl Med Commun 2000 0.76
48 Intraperitoneal chemotherapy for malignant peritoneal mesothelioma. Eur J Cancer 1991 0.76
49 Diagnosis and treatment of a carcinoid tumor using iodine-131 meta-iodobenzylguanidine. Clin Nucl Med 1986 0.75
50 Role of [131I]metaiodobenzylguanidine therapy in carcinoids. J Nucl Biol Med 1992 0.75
51 Hepatic failure due to liver metastases in breast cancer. Neth J Med 1985 0.75
52 Carcinoid tumors. N Engl J Med 1999 0.75
53 Comment on radiotherapy for treatment of localized gastrointestinal non-Hodgkin's lymphoma. Radiother Oncol 1998 0.75
54 Bioavailability of oral etoposide in gastric cancer. Eur J Cancer 1994 0.75
55 Mitoxantrone in metastatic apudomas: a phase II study of the EORTC Gastro-Intestinal Cancer Cooperative Group. Br J Cancer 1995 0.75
56 Gastrointestinal metastases in lobular breast cancer. Ann Oncol 2001 0.75
57 [Current possibilities in the treatment of severe stenosis of the major airways]. Ned Tijdschr Geneeskd 1992 0.75
58 [Helicobacter pylori infection and lymphoma of the stomach]. Ned Tijdschr Geneeskd 1995 0.75
59 Comment on "Adjuvant treatment of colon cancer. A plea for a large-scale European trial". Neth J Med 1994 0.75
60 Sequential 75SeHCAT imaging in addition to the conventional 75SeHCAT test: a necessity. Eur J Nucl Med 1995 0.75
61 Experience of discharge from colonoscopy of mutation negative HNPCC family members. J Med Genet 2003 0.75
62 [Diagnosis and therapy of neural crest tumors using I131 iodobenzylguanidine]. Ned Tijdschr Geneeskd 1988 0.75
63 Studies in primary biliary cirrhosis. Neth J Med 1981 0.75
64 Primary biliary cirrhosis: a changing clinical presentation. Neth J Med 1981 0.75
65 [Second tumors following treatment of Hodgkin's disease]. Ned Tijdschr Geneeskd 1988 0.75
66 Sequence-dependent toxicity profile in modified FAMTX (fluorouracil-adriamycin-methotrexate) chemotherapy with lenograstim support for advanced gastric cancer: a feasibility study. Pharmacol Res 2000 0.75
67 Monomeric (7S) IgM in primary biliary cirrhosis. Scand J Gastroenterol 1982 0.75
68 5-Fluorouracil plus tauromustine in advanced colorectal cancer: unexpected negative results. Eur J Cancer 1990 0.75
69 Cryoglobulins in primary biliary cirrhosis: prevalence and modulation by immunosuppressive therapy. Z Gastroenterol 1985 0.75
70 Long-term survival in two cases of colorectal carcinoma following a new chemotherapy regimen and subsequent metastasectomy. Eur J Surg Oncol 1995 0.75
71 Evaluation of a probabilistic model for staging of oesophageal carcinoma. Stud Health Technol Inform 2000 0.75
72 [The treatment of pancreatic carcinoma with cytostatic agents]. Ned Tijdschr Geneeskd 1987 0.75
73 [Treatment of colonic carcinoma with cytostatic agents]. Ned Tijdschr Geneeskd 1987 0.75
74 [Cytostatic agents in the treatment of stomach carcinoma]. Ned Tijdschr Geneeskd 1987 0.75
75 Gastrointestinal lymphomas--the Dutch experience. Recent Results Cancer Res 2000 0.75
76 Bioanalysis of m-iodobenzylguanidine in plasma by high-performance liquid chromatography after derivatization with benzoin. J Chromatogr B Biomed Sci Appl 1999 0.75
77 [Sealing esophagobronchial fistulae: better results with self expanding stents than with an esophagobronchial fistula]. Ned Tijdschr Geneeskd 1998 0.75
78 Tauromustine (TCNU) combined with 5-fluorouracil and leucovorin in the treatment of advanced colon cancer. Eur J Cancer 1993 0.75
79 Surgical repair of radiation damage of the rectum: a systematic approach to a difficult problem. Eur J Surg Oncol 1988 0.75
80 [Acute liver insufficiency caused by rifampicin-isoniazid]. Ned Tijdschr Geneeskd 1980 0.75
81 Treatment of liver metastases from colorectal cancer with continuous high dose intra-arterial floxuridine (FUDR) and systemic fluorouracil: a phase II study. Eur J Cancer Clin Oncol 1989 0.75
82 Diagnosis and treatment in metastatic adenocarcinoma of unknown primary tumour. Neth J Med 1988 0.75